Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
AssigneeThe University of British Columbia
InventorsJohn D. Steeves, Jason K. Dyer, Hans S. Keirstead
Life of this patent
Estimating the term…
Abstract
Novel compositions are described comprising the combined administration of serum complement proteins with complement-fixing antibodies. The antibodies specifically bind to one or more epitopes of myelin, and complement proteins. These compositions are useful for promoting regrowth, repair, and regeneration of neurons in the CNS of a mammalian subject. The compositions and method can be used following immediate or chronic injury.
Claims17
A kit for parenteral administration comprising one or more containers comprising
- (a) one or more complement-fixing human, recombinant human or humanized antibodies or fragments thereof in a sterile pharmaceutical carrier, wherein said antibodies or fragments comprise a complement-binding Fc region of a complement-fixing antibody which specifically binds to an epitope of a mammalian myelin selected from the group consisting of galactocerebroside (GalC), O4, Myelin Associated Glycoprotein (MAG), NOGO, NI220, NI-35/250, myelin oligodendrocyte glycoprotein (MOG) and arretin;
- and
- (b) complement protein in a sterile pharmaceutical carrier;
- wherein when (a) and (b) are administered together are effective to cause in vivo transient disruption and/or transient demyelination of mammalian neurons.
A kit for parenteral administration comprising one or more container means comprising
- (a) one or more complement-fixing human, recombinant human or humanized antibodies or fragments thereof in a sterile pharmaceutical carrier, wherein said antibodies or fragments comprise a complement-binding Fc region of a complement-fixing antibody which specifically binds to an epitope of a mammalian myelin selected from the group consisting of galactocerebroside (GalC), O4, Myelin Associated Glycoprotein (MAG), NOGO, NI220, NI-35/250, myelin oligodendrocyte glycoprotein (MOG) and arretin;
- and
- (b) complement protein in a sterile pharmaceutical carrier;
- wherein when (a) and (b) are administered together are effective to cause in vivo transient disruption and/or transient demyelination of mammalian neurons.
Dependencies are inferred from the claim text.